- Country: Czech Republic
- Summary: Immunoprepaity 2025-Ii
- CZT Ref No: 127662308
- Deadline: 07 Nov 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: CZK 57812000
- Notice Type: Tender
- Document Ref. No.: 655083-2025
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- The subject of the public contract is the supply of medicinal products intended for the therapy of serious chronic diseases in the total expected volume of 20,920 individual doses (ampoules) of medicinal products.
The subject of performance will be realized on the basis of the results of the completed tender for four years after the signing of the purchase contract.
Calmette-guerin, expected annual volume of 380 ampoules; expected annual volume of 35 ampoules; beta -1b, expected annual volume of 1,650 ampoules; the management, expected annual volume of 350 ampoules; Velolizumabu, estimated annual volume of 1,350 ampoules; the active substance of the natalizumab
natalizumabu, p... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINImmunoprepaity 2025-Ii - Czech Republic Tender
The UNIVERSITY HOSPITAL PILSEN, a Government sector organization in Czech Republic, has announced a new tender for Immunoprepaity 2025-Ii. This tender is published on CzechRepublicTenders under CZT Ref No: 127662308 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-11-07.
The estimated tender value is CZK 57812000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
